Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | First-in-human CLL1-CD33 compound CAR T-cells for AML

Fang Liu • 16 Jun 2018
EHA 2018
Acute Myeloid Leukemia Leukemia CAR-T

Dr Fang Liu, of Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China, discusses first-in-human CLL1-CD33 compound CAR T-cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia (AML). This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

More from Fang Liu

3:23
First-in-human trial of a BCMA-CD19 compound CAR in B-ALL
Fang Liu • 7 Dec 2019

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals